How to Get Rezdiffra (Resmetirom) in Arkansas

What Is Rezdiffra and Why Does It Matter for Arkansas Patients?

Rezdiffra (resmetirom) is the first FDA-approved medication specifically targeting MASH with liver fibrosis. The FDA granted accelerated approval on March 14, 2024, based on results from the MAESTRO-NASH trial [1]. Before this approval, no pharmacotherapy existed for MASH, a condition affecting an estimated 6 to 8 million Americans with significant fibrosis stages [2].

Arkansas ranks among states with the highest rates of obesity and type 2 diabetes, both independent risk factors for MASH progression. According to the CDC's Behavioral Risk Factor Surveillance System, Arkansas had an adult obesity prevalence of 40.6% in 2023, placing it in the top five nationally [3]. That epidemiologic burden means a substantial pool of Arkansas residents may qualify for resmetirom therapy.

The drug works as a thyroid hormone receptor beta (THR-β) agonist. It selectively activates the beta receptor in hepatocytes, reducing liver fat and inflammatory markers without stimulating the alpha receptor that drives cardiac effects. In MAESTRO-NASH (N=966), 25.9% of patients on the 80 mg dose and 29.9% on the 100 mg dose achieved NASH resolution with no worsening of fibrosis at 52 weeks, compared with 9.7% on placebo (P<0.001 for both comparisons) [1].

Step-by-Step: Getting a Rezdiffra Prescription in Arkansas

The process from initial evaluation to filled prescription typically spans two to six weeks, depending on insurance response times. Here is the sequence most patients follow.

1. Clinical evaluation and diagnosis confirmation. A gastroenterologist, hepatologist, or qualified primary care provider must document a MASH diagnosis. The FDA label specifies use in patients with noncirrhotic NASH (now termed MASH) and moderate to advanced hepatic fibrosis (stages F2-F3) [4]. Diagnosis relies on liver biopsy, FibroScan (vibration-controlled transient elastography), or MRI-based elastography combined with clinical markers.

2. Baseline laboratory workup. Before prescribing, the clinician orders a hepatic function panel (ALT, AST, alkaline phosphatase, total bilirubin), thyroid function tests (TSH and free T4), and a standard lipid panel. The prescribing information requires thyroid monitoring because resmetirom's mechanism of action involves thyroid hormone receptor activation [4]. Patients with uncontrolled hypothyroidism or TSH above the normal range should have thyroid function corrected before starting therapy.

3. Prescription and dosing. Dosing is weight-based: patients weighing <100 kg receive 80 mg once daily, while those at or above 100 kg receive 100 mg once daily [4]. The clinician sends the prescription to a specialty pharmacy.

4. Prior authorization (if required). Most commercial insurers and Arkansas Medicaid require prior authorization. The typical turnaround is 5 to 15 business days. Documentation is covered in detail below.

Telehealth Access to Resmetirom in Arkansas

Arkansas permits telehealth prescribing for Rezdiffra through both in-state and out-of-state licensed providers. This is a real option.

The Arkansas State Medical Board allows physicians to establish a patient-provider relationship via synchronous audio-video telemedicine under Act 203 of 2017, and the Arkansas State Board of Nursing extends prescriptive authority to APRNs practicing via telehealth under collaborative practice agreements. Patients in rural counties without access to a gastroenterologist or hepatologist can connect with specialists in Little Rock, Fayetteville, or out-of-state MASH-focused telehealth platforms.

A telehealth visit for resmetirom evaluation typically includes review of existing imaging or biopsy results, a medication reconciliation, and lab orders sent to a local draw site (Quest Diagnostics and Labcorp both operate multiple service centers across Arkansas). The Arkansas Department of Health maintains a list of licensed telehealth providers operating in the state.

One clinical consideration: if a patient has not yet undergone FibroScan or liver biopsy, the telehealth provider will need to refer to a local facility for staging. FibroScan is available at UAMS Medical Center in Little Rock, Mercy Hospital in Fort Smith, and several gastroenterology practices in Northwest Arkansas.

Arkansas Medicaid and Commercial Insurance Coverage

Arkansas Medicaid covers Rezdiffra under a limited prior authorization pathway. This means the drug is on formulary but requires the prescriber to submit clinical documentation before dispensing is approved.

The PA packet for Arkansas Medicaid typically requires: confirmed MASH diagnosis with fibrosis stage F2 or F3 documented by biopsy or validated noninvasive test, baseline liver function labs, documentation that the patient is engaged in lifestyle modification (diet and exercise), and confirmation that the patient does not have decompensated cirrhosis or Child-Pugh class B or C liver disease [4].

Commercial insurers in Arkansas (Blue Cross Blue Shield of Arkansas, QualChoice, Ambetter) each maintain their own PA criteria, but the clinical documentation requirements overlap substantially with Medicaid. According to a 2024 AASLD practice guidance update, payers are increasingly aligning PA criteria with the FDA-approved indication and the MAESTRO-NASH enrollment criteria [5].

The estimated wholesale acquisition cost (WAC) for Rezdiffra is approximately $47,400 per year. Madrigal Pharmaceuticals offers a patient assistance program (RezdiffrAssist) and a commercial copay card that may reduce out-of-pocket costs to $0 for eligible patients with commercial insurance [6]. Patients on Medicaid or other government-funded insurance are not eligible for the copay card but may qualify for the patient assistance program.

Dr. Zobair Younossi, chairman of the Global NASH Council, noted in a 2024 interview: "The approval of resmetirom changes the treatment algorithm for MASH. For the first time, we can offer patients a pharmacologic option that addresses the underlying liver disease rather than just managing metabolic comorbidities" [5].

Which Pharmacies in Arkansas Dispense Rezdiffra?

Rezdiffra is distributed through specialty pharmacy channels. Most patients will not pick it up at a retail CVS or Walgreens location.

The primary specialty pharmacy distributors for Rezdiffra include Optum Specialty Pharmacy, CVS Specialty, and Accredo (Express Scripts). These pharmacies ship directly to Arkansas addresses, typically via cold-chain-compliant overnight delivery. Arkansas-based 503A compounding pharmacies are licensed to compound resmetirom formulations under state pharmacy board regulations, though most patients access the commercially manufactured tablet.

Once the specialty pharmacy receives the prescription and PA approval, the typical ship time is 3 to 5 business days. The pharmacy will conduct a benefits investigation and contact the patient before shipment to confirm copay amounts and delivery details.

Patients who prefer to work with a local pharmacy can ask their prescriber to check whether UAMS Outpatient Pharmacy or Baptist Health pharmacy locations have established agreements with the manufacturer's distribution network.

Required Labs and Monitoring on Resmetirom

Baseline and ongoing monitoring keeps therapy safe. The prescribing information outlines specific requirements [4].

Before starting Rezdiffra:

• Hepatic panel: ALT, AST, alkaline phosphatase, total bilirubin, albumin
• Thyroid function: TSH and free T4 (resmetirom should not be initiated if TSH is above the upper limit of normal)
• Lipid panel: total cholesterol, LDL, HDL, triglycerides (resmetirom significantly lowers LDL; MAESTRO-NASH showed a 13.6% reduction in LDL cholesterol at 100 mg vs. placebo at 52 weeks [1])
• SHBG (sex hormone-binding globulin): may increase on therapy due to THR-β activation in hepatocytes

During treatment (every 3 to 6 months for the first year):

• Repeat hepatic panel to monitor for drug-induced liver injury (rare but included in the label)
• TSH and free T4 at 3 months, then every 6 months
• Lipid panel at 3 and 6 months

The MAESTRO-NASH safety data showed that the most common adverse events were diarrhea (26.5% on 100 mg vs. 16.8% on placebo) and nausea (22.1% vs. 12.5%) [1]. Most gastrointestinal symptoms were mild to moderate and resolved within the first 4 to 8 weeks of therapy.

Who Can Prescribe Rezdiffra in Arkansas?

Any Arkansas-licensed prescriber with the appropriate clinical competency can write a Rezdiffra prescription. That includes MDs, DOs, NPs (APRNs with prescriptive authority), and PAs.

In practice, most prescriptions originate from gastroenterologists or hepatologists because the drug requires a confirmed MASH diagnosis with fibrosis staging. Primary care physicians comfortable interpreting FibroScan results or liver biopsy reports can also prescribe. Arkansas-licensed NPs and PAs must practice under a collaborative practice agreement for Schedule II-V drugs, but resmetirom is not a controlled substance, so the standard prescriptive authority for non-controlled medications applies.

The American Association for the Study of Liver Diseases (AASLD) recommends that prescribing clinicians have experience interpreting noninvasive fibrosis markers and managing MASH, given the monitoring requirements [5]. Patients without an established relationship with a liver specialist can request a referral through their primary care provider or connect directly via a telehealth platform.

Prior Authorization Documentation: What Arkansas Payers Require

Prior authorization is the most common source of delay. Having complete documentation ready at the time of submission shortens the approval timeline.

Standard PA documentation checklist for Arkansas:

• Confirmed diagnosis of MASH (ICD-10 code K75.81)
• Fibrosis stage F2 or F3, documented by liver biopsy (METAVIR or Brunt classification) OR validated noninvasive test (FibroScan with liver stiffness measurement, FIB-4 index, or ELF score)
• Baseline lab values: ALT, AST, ALP, bilirubin, TSH, free T4
• Body weight (determines 80 mg vs. 100 mg dosing)
• Documentation of lifestyle counseling or nutritional referral
• Statement that the patient does not have decompensated cirrhosis, hepatocellular carcinoma, or active alcohol use disorder
• Prescriber specialty and NPI number

Arkansas Medicaid processes most Rezdiffra PAs within 10 to 15 business days. Commercial payers average 5 to 10 business days. If a PA is denied, the prescriber can submit a peer-to-peer review request, which involves a phone call between the prescribing physician and the payer's medical director.

Dr. Manal Abdelmalek, a hepatologist at the Mayo Clinic and investigator on the MAESTRO-NASH trial, has stated: "The fibrosis staging requirement in the FDA label is appropriate because these are the patients at highest risk for progression to cirrhosis and liver-related mortality. Noninvasive tests like FibroScan have made staging accessible without routine biopsy" [7].

Timeline: From First Visit to First Dose in Arkansas

Each step has a measurable window. Patients who arrive with existing imaging and labs move through the process faster.

| Step | Typical Duration | |---|---| | Initial consultation (in-person or telehealth) | 1 visit (same week if urgent) | | Lab draw and results | 2-5 business days | | FibroScan or imaging (if not already done) | 1-2 weeks for scheduling | | PA submission and approval | 5-15 business days | | Specialty pharmacy processing and shipment | 3-5 business days | | Total (new patient, no prior workup) | 3-6 weeks | | Total (existing workup, labs in hand) | 1-3 weeks |

Patients transferring an existing Rezdiffra prescription from another state can often bypass the diagnostic steps entirely. The receiving Arkansas prescriber verifies the diagnosis, confirms labs are current, and submits a new PA to the patient's Arkansas-based insurer.

MAESTRO-NASH: The Trial Behind the Approval

The Phase 3 MAESTRO-NASH trial, published in the New England Journal of Medicine in February 2024, randomized 966 patients with biopsy-confirmed NASH and fibrosis (stages F1B through F3) to resmetirom 80 mg, 100 mg, or placebo [1].

The dual primary endpoints at 52 weeks were NASH resolution (defined as a NAFLD Activity Score of ≤2 with no individual component score above 1, and no worsening of fibrosis) and a ≥1-stage improvement in fibrosis with no worsening of NAS. Results were definitive: 25.9% of the 80 mg group and 29.9% of the 100 mg group achieved NASH resolution, versus 9.7% on placebo. For the fibrosis endpoint, 24.2% (80 mg) and 25.9% (100 mg) achieved ≥1-stage fibrosis improvement, versus 14.2% on placebo [1].

These numbers drove the FDA's accelerated approval. Continued approval depends on confirmatory outcomes data from the ongoing MAESTRO-NASH-Outcomes trial, which is measuring cirrhosis progression, liver transplant, and liver-related death [8].

The LDL-lowering effect deserves separate attention. Resmetirom reduced LDL cholesterol by 13.6% (100 mg) and 10.4% (80 mg) at 24 weeks [1]. For MASH patients with concurrent dyslipidemia (a common overlap), this provides a secondary cardiometabolic benefit that most payers recognize as clinically meaningful.

Safety Considerations Specific to Arkansas Patients

Two practical points apply to the Arkansas patient population.

First, thyroid disease prevalence. Arkansas has a high rate of hypothyroidism, partly attributable to iodine-insufficient dietary patterns in some rural areas. Patients with untreated or poorly controlled hypothyroidism (TSH above the upper limit of normal) should not start resmetirom until thyroid function is optimized [4]. The prescribing information does not contraindicate concurrent levothyroxine use, but TSH must be monitored more frequently (every 8 to 12 weeks) in patients on both medications.

Second, polypharmacy. Arkansas Medicaid beneficiaries with MASH frequently carry comorbid type 2 diabetes, hypertension, and dyslipidemia. Resmetirom has a known interaction with certain OATP1B1/1B3 substrates (including some statins). Atorvastatin exposure may increase when co-administered with resmetirom, so dose adjustment or enhanced monitoring of statin-related myopathy symptoms is warranted [4].